Aroa Biosurgery Gestione
Criteri Gestione verificati 3/4
Al momento non disponiamo di informazioni sufficienti sull'amministratore delegato.
Informazioni chiave
Brian Ward
Amministratore delegato
NZ$1.7m
Compenso totale
| Percentuale dello stipendio del CEO | 33.03% |
| Mandato del CEO | 18.8yrs |
| Proprietà del CEO | 9.6% |
| Durata media del management | 6yrs |
| Durata media del Consiglio di amministrazione | 6.7yrs |
Aggiornamenti recenti sulla gestione
Recent updates
Aggiornamento narrativa • Jul 06
ARX: Higher Multiple And Earnings Outlook Will Support Future Upside
Analysts have lifted their Aroa Biosurgery price target from A$1.16 to A$1.35, citing updated assumptions around discount rates, revenue growth, profit margins, and a higher future P/E multiple in their valuation work. What's in the News Aroa Biosurgery issued earnings guidance for fiscal 2026, indicating expected total revenue of approximately NZ$104 million on an actual basis, according to company guidance.
Aggiornamento narrativa • Jun 22
ARX: Positive Trial Success And Growing Portfolio Will Support Future Earnings Power
Analysts have maintained their Aroa Biosurgery fair value estimate at A$1.09. They applied a slightly higher discount rate and made only minor adjustments to revenue growth, profit margin and future P/E assumptions to support their unchanged price target view.Aggiornamento narrativa • Jun 05
ARX: Positive Trial Results Will Underpin Future Earnings Power
Analysts have nudged their price target for Aroa Biosurgery higher to A$1.09 from A$1.07, reflecting updated assumptions around discount rates, revenue growth, profit margins, and future P/E expectations. What's in the News Aroa Biosurgery issued earnings guidance for fiscal 2026, projecting total revenue of about NZ$104 million on an actual basis, citing stronger than expected sales in the Myriad portfolio and favourable foreign exchange movements.Aggiornamento narrativa • May 03
ARX: Positive Wound Trial Results Will Support Stronger Future Profitability
Analysts have lifted their price target for Aroa Biosurgery from A$0.83 to A$1.07, citing updated assumptions that include a higher discount rate, a slightly adjusted revenue growth outlook, a stronger forecast profit margin, and a lower future P/E multiple. What's in the News Aroa Biosurgery reported completion of its randomised controlled trial of Symphony, a skin substitute designed for hard to heal wounds such as diabetic foot ulcers and venous leg ulcers, with a preliminary read out indicating the primary endpoint was achieved (Key Developments).
Nuova narrativa • Apr 08
Reimbursement Shifts And Partner Dependence Will Reshape Tissue Regeneration Prospects Over Time
Catalysts About Aroa Biosurgery Aroa Biosurgery develops and supplies biologically derived soft tissue regeneration products used in wound care, reconstruction and surgical procedures. What are the underlying business or industry changes driving this perspective?Nuova narrativa • Mar 24
Outpatient Expansion And Surgical Partnerships Will Transform Long Term Prospects For This Biologics Supplier
Catalysts About Aroa Biosurgery Aroa Biosurgery develops and supplies biologically derived soft tissue regeneration products used in wound care, trauma, burns and reconstructive surgery. What are the underlying business or industry changes driving this perspective?Articolo di analisi • Nov 28
Aroa Biosurgery Limited (ASX:ARX) Just Reported Interim Earnings: Have Analysts Changed Their Mind On The Stock?
Aroa Biosurgery Limited ( ASX:ARX ) last week reported its latest half-yearly results, which makes it a good time for...
Nuova narrativa • Apr 26
Lebanon, Vietnam, And Saudi Arabia Approvals Will Secure Market Presence
Expansion into international markets and positive clinical outcomes suggest potential revenue growth as new regions adopt Aroa's cost-effective products.Articolo di analisi • Apr 07
Why Investors Shouldn't Be Surprised By Aroa Biosurgery Limited's (ASX:ARX) 26% Share Price Plunge
Unfortunately for some shareholders, the Aroa Biosurgery Limited ( ASX:ARX ) share price has dived 26% in the last...Articolo di analisi • Mar 24
Aroa Biosurgery (ASX:ARX) Is In A Strong Position To Grow Its Business
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...Articolo di analisi • Feb 15
Why Investors Shouldn't Be Surprised By Aroa Biosurgery Limited's (ASX:ARX) 26% Share Price Plunge
Aroa Biosurgery Limited ( ASX:ARX ) shareholders won't be pleased to see that the share price has had a very rough...Articolo di analisi • Dec 04
Aroa Biosurgery Limited (ASX:ARX) Held Back By Insufficient Growth Even After Shares Climb 26%
Aroa Biosurgery Limited ( ASX:ARX ) shares have continued their recent momentum with a 26% gain in the last month...Articolo di analisi • Nov 27
The Aroa Biosurgery Limited (ASX:ARX) Interim Results Are Out And Analysts Have Published New Forecasts
It's been a good week for Aroa Biosurgery Limited ( ASX:ARX ) shareholders, because the company has just released its...Articolo di analisi • Nov 13
We're Not Worried About Aroa Biosurgery's (ASX:ARX) Cash Burn
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...Articolo di analisi • Aug 22
Take Care Before Jumping Onto Aroa Biosurgery Limited (ASX:ARX) Even Though It's 29% Cheaper
Aroa Biosurgery Limited ( ASX:ARX ) shareholders won't be pleased to see that the share price has had a very rough...Articolo di analisi • Jun 12
Investors Aren't Entirely Convinced By Aroa Biosurgery Limited's (ASX:ARX) Revenues
With a price-to-sales (or "P/S") ratio of 3.3x Aroa Biosurgery Limited ( ASX:ARX ) may be sending very bullish signals...Articolo di analisi • Mar 25
Here's Why We're Not At All Concerned With Aroa Biosurgery's (ASX:ARX) Cash Burn Situation
Just because a business does not make any money, does not mean that the stock will go down. For example, although...Articolo di analisi • Jan 30
Why Investors Shouldn't Be Surprised By Aroa Biosurgery Limited's (ASX:ARX) 25% Share Price Plunge
Aroa Biosurgery Limited ( ASX:ARX ) shareholders that were waiting for something to happen have been dealt a blow with...Articolo di analisi • Nov 14
Aroa Biosurgery Limited's (ASX:ARX) Revenues Are Not Doing Enough For Some Investors
With a price-to-sales (or "P/S") ratio of 4.3x Aroa Biosurgery Limited ( ASX:ARX ) may be sending very bullish signals...Articolo di analisi • Nov 02
Industry Analysts Just Made A Captivating Upgrade To Their Aroa Biosurgery Limited (ASX:ARX) Revenue Forecasts
Shareholders in Aroa Biosurgery Limited ( ASX:ARX ) may be thrilled to learn that the analysts have just delivered a...Articolo di analisi • Oct 25
Aroa Biosurgery Limited's (ASX:ARX) Intrinsic Value Is Potentially 50% Above Its Share Price
Does the October share price for Aroa Biosurgery Limited ( ASX:ARX ) reflect what it's really worth? Today, we will...Articolo di analisi • May 13
We Think Aroa Biosurgery (ASX:ARX) Can Easily Afford To Drive Business Growth
Just because a business does not make any money, does not mean that the stock will go down. For example, although...Analisi delle retribuzioni degli amministratori delegati
| Data | Compenso totale | Stipendio | Utili della società |
|---|---|---|---|
| Mar 31 2026 | NZ$2m | NZ$574k | NZ$5m |
| Dec 31 2025 | n/a | n/a | NZ$1m |
| Sep 30 2025 | n/a | n/a | -NZ$2m |
| Jun 30 2025 | n/a | n/a | -NZ$3m |
| Mar 31 2025 | NZ$978k | NZ$569k | -NZ$4m |
| Dec 31 2024 | n/a | n/a | -NZ$6m |
| Sep 30 2024 | n/a | n/a | -NZ$8m |
| Jun 30 2024 | n/a | n/a | -NZ$9m |
| Mar 31 2024 | NZ$1m | NZ$583k | -NZ$11m |
| Dec 31 2023 | n/a | n/a | -NZ$9m |
| Sep 30 2023 | n/a | n/a | -NZ$8m |
| Jun 30 2023 | n/a | n/a | -NZ$4m |
| Mar 31 2023 | NZ$1m | NZ$552k | -NZ$396k |
| Dec 31 2022 | n/a | n/a | -NZ$1m |
| Sep 30 2022 | n/a | n/a | -NZ$2m |
| Jun 30 2022 | n/a | n/a | -NZ$5m |
| Mar 31 2022 | NZ$1m | NZ$542k | -NZ$8m |
| Dec 31 2021 | n/a | n/a | -NZ$10m |
| Sep 30 2021 | n/a | n/a | -NZ$11m |
| Jun 30 2021 | n/a | n/a | -NZ$15m |
| Mar 31 2021 | NZ$2m | NZ$483k | -NZ$19m |
Compensazione vs Mercato: La retribuzione totale di Brian ($USD 1.01M ) è superiore alla media delle aziende di dimensioni simili nel mercato Australian ($USD 320.50K ).
Compensazione vs guadagni: La retribuzione di Brian è stata coerente con le performance aziendali dell'ultimo anno.
AMMINISTRATORE DELEGATO
Brian Ward
18.8yrs
Mandato
NZ$1,739,168
Compensazione
Dr. Brian Ward, B.V.Sc, MBA(dist) has been Executive Director at Aroa Biosurgery Limited since September 21, 2007 and serves as its Managing Director and Chief Executive Officer. He has founded Aroa Biosur...
Gruppo dirigente
| Nome | Posizione | Mandato | Compensazione | Proprietà |
|---|---|---|---|---|
| Founder | no data | NZ$1.74m | 9.58% A$ 19.9m | |
| CFO & Joint Company Secretary | 6.4yrs | NZ$627.01k | Nessun dato | |
| Chief Operating Officer | no data | Nessun dato | Nessun dato | |
| Chief of Technical Operations | no data | Nessun dato | Nessun dato | |
| Chief Scientific Officer | 4.6yrs | Nessun dato | 0.95% A$ 2.0m | |
| Joint Company Secretary | 6yrs | Nessun dato | Nessun dato | |
| Vice President of Medical Affairs | no data | Nessun dato | Nessun dato | |
| Media Executive | no data | Nessun dato | Nessun dato |
6.0yrs
Durata media
Gestione esperta: Il team dirigenziale di ARX è esperto e expertise (durata media dell'incarico 6 anni).
Membri del Consiglio di amministrazione
| Nome | Posizione | Mandato | Compensazione | Proprietà |
|---|---|---|---|---|
| Founder | 18.8yrs | NZ$1.74m | 9.58% A$ 19.9m | |
| Independent Non-Executive Director | less than a year | NZ$33.33k | 0.14% A$ 300.0k | |
| Independent Non-Executive Chairperson | 14.9yrs | NZ$151.37k | 0.82% A$ 1.7m | |
| Independent Non-Executive Director | 6.7yrs | NZ$123.31k | 0.24% A$ 499.5k | |
| Non-Executive Director | 18.3yrs | NZ$90.91k | 5.8% A$ 12.0m | |
| Independent Non-Executive Director | 3.7yrs | NZ$154.66k | 0.13% A$ 261.8k | |
| Independent Non-Executive Director | 2.3yrs | NZ$155.99k | 0.041% A$ 84.1k |
6.7yrs
Durata media
Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di ARX sono considerati esperti (durata media dell'incarico 6.7 anni).
Analisi aziendale e situazione dei dati finanziari
| Dati | Ultimo aggiornamento (ora UTC) |
|---|---|
| Analisi dell'azienda | 2026/07/17 11:53 |
| Prezzo dell'azione a fine giornata | 2026/07/17 00:00 |
| Utili | 2026/03/31 |
| Utili annuali | 2026/03/31 |
Fonti dei dati
I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC. I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.
| Pacchetto | Dati | Tempistica | Esempio Fonte USA * |
|---|---|---|---|
| Dati finanziari della società | 10 anni |
| |
| Stime di consenso degli analisti | +3 anni |
|
|
| Prezzi di mercato | 30 anni |
| |
| Proprietà | 10 anni |
| |
| Gestione | 10 anni |
| |
| Sviluppi principali | 10 anni |
|
* Esempio per i titoli statunitensi, per i titoli non statunitensi si utilizzano forme e fonti normative equivalenti.
Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più.
Modello di analisi e Snowflake
I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina GitHub; abbiamo anche delle guide su come utilizzare i nostri report e dei tutorial su YouTube.
Scoprite il team di livello mondiale che ha progettato e realizzato il modello di analisi Simply Wall St.
Metriche di settore e industriali
Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su Github.
Fonti analitiche
Aroa Biosurgery Limited è coperta da 4 analisti. 3 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.
| Analista | Istituzione |
|---|---|
| John Hester | Bell Potter |
| Shane Storey | Canaccord Genuity |
| Scott Power | Morgans Financial Limited |